Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
79.96
-1.56 (-1.91%)
At close: Jul 18, 2025, 4:00 PM
80.15
+0.19 (0.24%)
After-hours: Jul 18, 2025, 7:59 PM EDT
Merck & Co. Revenue
Merck & Co. had revenue of $15.53B in the quarter ending March 31, 2025, a decrease of -1.56%. This brings the company's revenue in the last twelve months to $63.92B, up 4.10% year-over-year. In the year 2024, Merck & Co. had annual revenue of $64.17B with 6.74% growth.
Revenue (ttm)
$63.92B
Revenue Growth
+4.10%
P/S Ratio
3.16
Revenue / Employee
$852,293
Employees
75,000
Market Cap
200.78B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
Abbott Laboratories | 43.11B |
MRK News
- 2 days ago - July's 5 Dividend Growth Stocks With Yields Up To 7.96% - Seeking Alpha
- 2 days ago - Livestock Identification Company Evaluation Report 2025 | Merck, Shearwell, Datamars Drive Innovations with Comprehensive Tagging and Tracking Solutions - GlobeNewsWire
- 3 days ago - Merck & Co., Inc. (MRK) Presents at HIV Investor Event Transcript - Seeking Alpha
- 4 days ago - Why Merck Is A Better Dividend Stock Than Gilead Sciences - Seeking Alpha
- 4 days ago - Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment - GlobeNewsWire
- 6 days ago - Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill - Business Wire
- 8 days ago - VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA - Business Wire
- 9 days ago - Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap - Forbes